SMAD2 and metastatic malignant neoplasm in the lymph nodes: The univariate analysis indicated that poor survival was significantly (p < 0.001) correlated with periostin-positive expression, Smad2/3-positive expression (p < 0.001), age ≥ 65 years (p = 0.021), poorer differentiation (p < 0.001), lymph node metastasis (p < 0.001), lymphatic invasion (p = 0.010), and venous invasion (p = 0.010).